Why the study?
Heart failure has been an under-recognized complication of arrhythmogenic cardiomyopathy, and updated clinical management guidelines warranted a comprehensive review.
This review summarizes the updated clinical management guidelines and research progress regarding the epidemiology, clinical characteristics, risk stratification, and therapeutics of heart failure in patients with arrhythmogenic cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Updated HF guidelines in ACM warrant clinical awareness; leaves open optimal strategies for prospective validation.
Arrhythmogenic cardiomyopathy (ACM) is a rare inherited cardiomyopathy characterized as fibro-fatty replacement, and a common cause for sudden cardiac death in young athletes. Development of heart failure (HF) has been an under-recognized complication of ACM for a long time. The current clinical management guidelines for HF in ACM progression have nowadays been updated. Thus, a comprehensive review for this great achievement in our understanding of HF in ACM is necessary. In this review, we aim to describe the research progress on epidemiology, clinical characteristics, risk stratification and therapeutics of HF in ACM.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: